Question 1

The reptilase test will be abnormally prolonged:

Accepted Answer

A)  In hypofibrinogenemia 
B)  If heparin is present in the sample 
C)  When the patient is on anti-vitamin K therapy 
D)  If the patient has had a recent thrombotic episode 
E)  All of the above 
A)  In hypofibrinogenemia 
B)  If heparin is present in the sample 
C)  When the patient is on anti-vitamin K therapy 
D)  If the patient has had a recent thrombotic episode 
E)  All of the above A

Question 2

Enzyme-specific synthetic substrates used in coagulation studies are based on the principle of amino acids of the substrate on the protein molecule fitting into the active sites and the binding sites of the __________.

Accepted Answer

A)  Substrate 
B)  Enzyme 
C)  Ligan D 
D)  Hapten 
E)  None of the above 
A)  Substrate 
B)  Enzyme 
C)  Ligan D 
D)  Hapten 
E)  None of the above B

Question 3

Synthetic chromogenic and fluorogenic assays are available for coagulation studies in the evaluation of:

Accepted Answer

A)  Plasmin 
B)  Plasminogen activator 
C)  Antithrombin III 
D)  Heparin 
E)  All of the above 
A)  Plasmin 
B)  Plasminogen activator 
C)  Antithrombin III 
D)  Heparin 
E)  All of the above E

Question 4

In the presence of a factor VIII inhibitor, the Bethesda titer should be determined in the management of a patient with __________ when therapy involves Factor VIII concentrates.

Accepted Answer

A)  Hemophilia 
B)  vWD 
C)  Thalassemia 
D)  Iron-deficiency anemia 
E)  None of the above 
A)  Hemophilia 
B)  vWD 
C)  Thalassemia 
D)  Iron-deficiency anemia 
E)  None of the above

Question 5

The __________ is the assay used for the one-stage quantitative method for factors VIII, IX, XI, and XII?

Accepted Answer

A)  PT 
B)  APTT 
C)  TT 
D)  Fibrinogen assay 
E)  None of the above 
A)  PT 
B)  APTT 
C)  TT 
D)  Fibrinogen assay 
E)  None of the above

Question 6

In the one-stage quantitative assay for factors II, V, VII, and X the __________ is the test system used, with specific-factor-deficient plasmas added to normalize all other factors but the one being measured.

Accepted Answer

A)  PT 
B)  APTT 
C)  Whole blood clotting time 
D)  Fibrinogen test 
E)  None of the above 
A)  PT 
B)  APTT 
C)  Whole blood clotting time 
D)  Fibrinogen test 
E)  None of the above

Question 7

The chromogenic anti-factor Xa assay is used to monitor:

Accepted Answer

A)  Coumarin 
B)  Low molecular weight heparin 
C)  Unfractionated heparin 
D)  Vitamin K 
E)  B and C 
A)  Coumarin 
B)  Low molecular weight heparin 
C)  Unfractionated heparin 
D)  Vitamin K 
E)  B and C

Question 8

In the fibrinogen activity assay, a prolonged clotting time obtained when testing patient plasma indicates:

Accepted Answer

A)  Increased fibrinogen (800 mg/dL or more) 
B)  Decreased fibrinogen (50 mg/dL or less) 
C)  Pregnancy 
D)  A and C 
E)  None of the above 
A)  Increased fibrinogen (800 mg/dL or more) 
B)  Decreased fibrinogen (50 mg/dL or less) 
C)  Pregnancy 
D)  A and C 
E)  None of the above

Question 9

In the absence of factor XIII, the hydrogen-bonded fibrin polymers are soluble in __________ or 1% monochloroacetic acid.

Accepted Answer

A)  KOH 
B)  5 M urea 
C)  Hydroxychlorate 
D)  5 M boric acid 
E)  None of the above 
A)  KOH 
B)  5 M urea 
C)  Hydroxychlorate 
D)  5 M boric acid 
E)  None of the above

Question 10

Platelet aggregation studies use __________.

Accepted Answer

A)  Platelet-rich plasma (250,000-350,000 plt count) 
B)  Platelet-poor plasma (<10,000 plt count) 
C)  Cryoprecipitate 
D)  Whole blood 
E)  None of the above 
A)  Platelet-rich plasma (250,000-350,000 plt count) 
B)  Platelet-poor plasma (<10,000 plt count) 
C)  Cryoprecipitate 
D)  Whole blood 
E)  None of the above

Question 11

The APTT is commonly used to monitor __________ therapy.

Accepted Answer

A)  Coumarin 
B)  Unfractionated heparin 
C)  Low molecular weight heparin 
D)  Vitamin K 
E)  None of the above 
A)  Coumarin 
B)  Unfractionated heparin 
C)  Low molecular weight heparin 
D)  Vitamin K 
E)  None of the above

Question 12

When a factor deficiency is present, there will be a correction of the abnormal APTT by __________ of normal plasma.

Accepted Answer

A)  75-90% 
B)  50-75% 
C)  10-25% 
D)  25-50% 
E)  None of the above 
A)  75-90% 
B)  50-75% 
C)  10-25% 
D)  25-50% 
E)  None of the above

Question 13

In the factor XIII screening test, the presence of a formal clot after 24 hours indicates a plasma factor XIII concentration of __________ of normal.

Accepted Answer

A)  1% 
C)  5-10% 
D)  10-20% 
E)  None of the above 
A)  1% 
C)  5-10% 
D)  10-20% 
E)  None of the above

Question 14

What is the anticoagulant used in a sample to be tested for APTT?

Accepted Answer

A)  Sodium oxalate 
B)  Sodium citrate, 3.2% 
C)  Sodium heparin 
D)  EDTA 
E)  None of the above 
A)  Sodium oxalate 
B)  Sodium citrate, 3.2% 
C)  Sodium heparin 
D)  EDTA 
E)  None of the above

Question 15

If fibrin is discovered in a citrated plasma sample, the following test(s) will not be affected and can still be run:

Accepted Answer

A)  PT 
B)  APTT 
C)  Thrombin time 
D)  All of the above 
E)  None of the above 
A)  PT 
B)  APTT 
C)  Thrombin time 
D)  All of the above 
E)  None of the above

Question 16

In performing a one-stage quantitative assay method for factor II, results are obtained from an activity curve made from dilutions of normal reference plasma and factor __________ plasma.

Accepted Answer

A)  II 
B)  II-deficient 
C)  V 
D)  V-deficient 
E)  None of the above 
A)  II 
B)  II-deficient 
C)  V 
D)  V-deficient 
E)  None of the above

Question 17

Reptilase hydrolyzes the fibrinopeptide __________ from the intact fibrinogen molecule in contrast to thrombin, which hydrolyzes fibrinopeptide __________ from fibrinogen.

Accepted Answer

A)  A, A/B 
B)  A/A, B 
C)  A, B 
D)  B, A 
E)  None of the above 
A)  A, A/B 
B)  A/A, B 
C)  A, B 
D)  B, A 
E)  None of the above

Question 18

Stabilization of the fibrin clot depends on plasma factor __________, which converts hydrogen bonds to covalent bonds by transamination.

Accepted Answer

A)  X 
B)  XI 
C)  XII 
D)  XIII 
E)  None of the above 
A)  X 
B)  XI 
C)  XII 
D)  XIII 
E)  None of the above

Question 19

The PT test is sensitive to the vitamin __________ factors and therefore useful as a means of monitoring oral anticoagulant therapy.

Accepted Answer

A)  K-independent 
B)  D-dependent 
C)  K-dependent 
D)  D-independent 
E)  None of the above 
A)  K-independent 
B)  D-dependent 
C)  K-dependent 
D)  D-independent 
E)  None of the above

Question 20

A thrombin time test was performed and the resulting clotting time exceeded the reference range. A 1:1 mixing study with normal pooled plasma was done that corrected the result to the normal range. Which abnormality is suspected?

Accepted Answer

A)  Thrombocytosis 
B)  Fibrinogen deficiency 
C)  Plasmin deficiency 
D)  Circulating inhibitor 
E)  None of the above 
A)  Thrombocytosis 
B)  Fibrinogen deficiency 
C)  Plasmin deficiency 
D)  Circulating inhibitor 
E)  None of the above

Exam 33: Coagulation Procedures

The reptilase test will be abnormally prolonged:

Enzyme-specific synthetic substrates used in coagulation studies are based on the principle of amino acids of the substrate on the protein molecule fitting into the active sites and the binding sites of the __________.

Synthetic chromogenic and fluorogenic assays are available for coagulation studies in the evaluation of:

In the presence of a factor VIII inhibitor, the Bethesda titer should be determined in the management of a patient with __________ when therapy involves Factor VIII concentrates.

The __________ is the assay used for the one-stage quantitative method for factors VIII, IX, XI, and XII?

In the one-stage quantitative assay for factors II, V, VII, and X the __________ is the test system used, with specific-factor-deficient plasmas added to normalize all other factors but the one being measured.

The chromogenic anti-factor Xa assay is used to monitor:

In the fibrinogen activity assay, a prolonged clotting time obtained when testing patient plasma indicates:

In the absence of factor XIII, the hydrogen-bonded fibrin polymers are soluble in __________ or 1% monochloroacetic acid.

Platelet aggregation studies use __________.

The APTT is commonly used to monitor __________ therapy.

When a factor deficiency is present, there will be a correction of the abnormal APTT by __________ of normal plasma.

In the factor XIII screening test, the presence of a formal clot after 24 hours indicates a plasma factor XIII concentration of __________ of normal.

What is the anticoagulant used in a sample to be tested for APTT?

If fibrin is discovered in a citrated plasma sample, the following test(s) will not be affected and can still be run:

In performing a one-stage quantitative assay method for factor II, results are obtained from an activity curve made from dilutions of normal reference plasma and factor __________ plasma.

Reptilase hydrolyzes the fibrinopeptide __________ from the intact fibrinogen molecule in contrast to thrombin, which hydrolyzes fibrinopeptide __________ from fibrinogen.

Stabilization of the fibrin clot depends on plasma factor __________, which converts hydrogen bonds to covalent bonds by transamination.

The PT test is sensitive to the vitamin __________ factors and therefore useful as a means of monitoring oral anticoagulant therapy.

A thrombin time test was performed and the resulting clotting time exceeded the reference range. A 1:1 mixing study with normal pooled plasma was done that corrected the result to the normal range. Which abnormality is suspected?

Morphology of Human Blood and Marrow Cells: Hematopoiesis

Bone Marrow

The Red Blood Cell: Structure and Function

Anemia: Diagnosis and Clinical Considerations

Evaluation of Red Blood Cell Morphology and Introduction to Platelet and White Blood Cell Morphology

Iron Metabolism and Hypochromic Anemias

Megaloblastic Anemias

Aplastic Anemia Including Pure Red Cell Aplasia and Congenital Dyserythropoietic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Introduction to Hemolytic Anemias: Intracorpuscular Defects: I Hereditary Defects of the Red Cell Membrane

Hemolytic Anemias: Intracorpuscular Defects: II Hereditary Enzyme Deficiencies

Hemolytic Anemias: Intracorpuscular Defects: III the Hemoglobinopathies

Hemolytic Anemias: Intracorpuscular Defects: Iv Thalassemia

Hemolytic Anemias: Extracorpuscular Defects

Hypoproliferative Anemia: Anemia Associated With Systemic Diseases

Cell Biology, Disorders of Neutrophils, Infectious Mononucleosis, and Reactive Lymphocytosis

Introduction to Leukemia and the Acute Leukemias

Chronic Myeloproliferative Disorders I: Chronic Myelogenous Leukemia

Chronic Myeloproliferative Disorders Ii: Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders

The Lymphomas

Multiple Myeloma and Related Plasma Cell Disorders

Lipid Lysosomal Storage Diseases and Histiocytosis

Introduction to Hemostasis

Disorders of Primary Hemostasis: Quantitative and Qualitative Platelet Disorders and Vascular Disorders

Disorders of Plasma Clotting Factors

Interaction of the Fibrinolytic, Coagulation, and Kinin Systems; Disseminated Intravascular Coagulation; and Related Pathology

Introduction to Thrombosis and Anticoagulant Therapy

Quality Control in the Hematology Laboratory

Body Fluid Examination: the Qualitative, Quantitative, and Morphologic Analysis of Serous, Cerebrospinal, and Synovial Fluids

Hematology Methods

Principles of Automated Differential Analysis

Applications of Flow Cytometry to Hematology and Hemostasis

Molecular Diagnostic Techniques in Hematopathology

Special Stainscytochemistry

Filters

Reptilase hydrolyzes the fibrinopeptide from the intact fibrinogen molecule in contrast to thrombin, which hydrolyzes fibrinopeptide from fibrinogen.